Lyfegen, which provides a platform for value-based contracting for high-cost medication, introduced it had raised $8 million in Collection A funding.
The spherical was led by aMoon, with participation from APEX Ventures and different traders. The startup, which is headquartered in Switzerland and the U.S., provides software program that goals to assist pharma firms, payers, suppliers and medical know-how firms undertake value-based contracts. It features a library of contracts, instruments to simulate how fashions will work earlier than implementing them, and information assortment to trace efficiency and outcomes.
“We at present work with main authorities payers and medical insurance firms in Europe, the U.S. and the Center East, and among the world’s largest pharma firms,” Girisha Fernando, CEO and founding father of Lyfegen, mentioned in a press release.
“Our plan now’s to additional increase our presence within the U.S., partnering with each personal and public healthcare insurance coverage firms. The transfer away from volume-based healthcare has by no means been extra wanted, and we’re completely satisfied to play an vital position within the shift to value-based contracting.”
Good stethoscope firm Eko acquired a $2.7 million grant from the Nationwide Institutes of Well being to develop a machine studying algorithm that detects and classifies pulmonary hypertension.
The Small Enterprise Innovation Analysis (SBIR) Direct Section II grant will go towards an algorithm that makes use of phonocardiogram (PCG) and electrocardiogram (ECG) information collected by Eko’s stethoscopes to seek out pulmonary hypertension, or hypertension, that impacts arteries within the lungs and the proper facet of coronary heart.
Eko has beforehand partnered with Lifespan Well being System’s Cardiovascular Institute to gather real-world PCG and ECG information that can be a part of the algorithm’s improvement.
“The main purpose of this research is to find out whether or not an Eko algorithm primarily based on phonocardiography coupled with electrocardiography can determine the presence and severity of pulmonary hypertension when in comparison with the present gold normal,” mentioned Dr. Gaurav Choudhary, principal investigator and director of cardiovascular analysis on the Lifespan Cardiovascular Institute.
“This machine studying algorithm has the potential to be a low price, simply implementable and sustainable medical know-how that assists healthcare professionals in figuring out extra sufferers with pulmonary hypertension.”
Eko mentioned that is their fourth SBIR grant. The corporate just lately acquired FDA 510(okay) clearance for an algorithm that detects and characterizes coronary heart murmurs in grownup and pediatric sufferers.
Halo, which provides a platform that goals to attach firms and scientists for analysis and improvement, raised $2.6 million in seed funding.
Contributors within the spherical embody Uneven Capital Companions, Village International, AirAngels, 23andMe cofounder and CEO Anne Wojcicki, cofounder and CTO of e-mail shopper Superhuman Conrad Irwin, and Rachel Hepworth, head of promoting at organizational software program firm Notion.
The platform permits biopharma, medical system, shopper items and agriculture firms to publish requests for proposals for particular wants or open calls round common analysis pursuits. Scientists can then reply with their proposals, and corporations can choose researchers for partnerships.
Halo plans to make use of the seed to rent new employees, develop new collaboration options on the platform and increase its community of scientists.
“Collaborating in R&D is simply as a lot about relationships as it’s concerning the analysis itself. Nonetheless, firms nonetheless depend on practices that do not scale, like listening to a chat at a convention or studying a journal article. This limits companies to a handful of current relationships and pure happenstance,” Kevin Leland, founder and CEO of Halo, mentioned in a press release.
“Halo connects company R&D groups straight with scientists. Via our platform, we engineer serendipity so firms can rapidly and simply scout for brand spanking new applied sciences, increase their networks globally and construct relationships with scientists 12 months spherical.”